New eye drop TFC-003 aims to lower glaucoma pressure
NCT ID NCT07662759
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests TFC-003, a new eye drop, in 188 adults with primary open-angle glaucoma or ocular hypertension. Participants use the drops twice daily for up to 24 weeks. The main goal is to see if TFC-003 lowers eye pressure better than an active control. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TFC-003 eye drops
- What this could lead to
- If successful, this could provide a new treatment option to help control eye pressure in people with glaucoma or ocular hypertension.
- What could go wrong
- This is a phase 3 trial, but results may not confirm superiority over existing treatments. Side effects or lack of long-term benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLAUCOMA OPEN-ANGLE PRIMARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kukje Pharma
RECRUITINGSeongnam, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which laser best tames glaucoma pressure?
- Could a single eye implant replace years of glaucoma drops?
- Which eye implant best tames glaucoma? a head-to-head trial aims to find out.
- One drop before the laser: could this simple step save your sight?
- Eye implant could offer long-term pressure control for glaucoma patients
- Eye implant could replace daily drops for glaucoma